Esbriet is an oral anti-fibrotic medicine approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF), and is available in approximately 40 countries worldwide. Esbriet has Orphan Drug Designation and was approved for use in Europe in 2011 in adults with mild-to-moderate IPF, and in the US in people with IPF in October 2014.
In 2017, the U.S. Food and Drug Administration (FDA) and the European Commission approved the Esbriet 801 mg and 267 mg tablets as an alternative to the original capsule formulation. The new 801 mg tablets offer people with IPF a maintenance option for taking Esbriet with fewer pills per day.
In 2019, the U.S. Food and Drug Administration (FDA) granted Breakthrough Designation status for Esbriet in unclassifiable interstitial lung disease (uILD).
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.